Psilocybin for addiction treatment vs. ibogaine — what does research show for each?
48 replies · Science & Research
I have a family member with opioid use disorder and I'm trying to understand the research landscape for psychedelic-assisted addiction treatment. I keep seeing both psilocybin and ibogaine mentioned but they seem to be used for different things. Can someone explain the evidence base and practical differences?
Psilocybin for addiction: Most studied for alcohol use disorder (AUD) and tobacco (nicotine). Matthew Johnson's Johns Hopkins study (2014) showed 80% of participants abstinent from tobacco at 6 months — exceptional compared to standard treatments (~35%). The 2022 AUD trial showed dramatic reduction in heavy drinking days. For opioids specifically, psilocybin research is early-stage — mechanisms are different and opioid neuroadaptation is more severe.
Ibogaine for opioids: Ibogaine interrupts opioid withdrawal physically (via kappa-opioid receptor activity) in a way psilocybin does not — it literally stops acute withdrawal. The Stanford 2024 study in veterans showed significant reduction in PTSD and depression as well. The limitation: ibogaine has a narrow therapeutic window and real cardiac risk (QT prolongation, arrhythmia risk). It requires medical supervision, ECG monitoring, and is not appropriate for home use. Currently Schedule I in US with limited legal access.
For your family member and opioids specifically: the most evidence-based psychedelic route is through a supervised ibogaine clinic (legal in Mexico, Costa Rica, and other countries). MAPS and ATAI Life Sciences both have ibogaine clinical trials recruiting. Psilocybin is not currently a first-line evidence-based option for opioid use disorder, though research is expanding.
45 more replies — forum posting coming soon.